Adeno-associated virus (AAV) is the most commonly used viral vector for both biological and gene therapeutic applications. Although many methods have been developed to measure quantity attributes of AAV, they are often technically challenging and time-consuming. Here, we report a method to titer AAV with GelGreen® dye, a safe green fluorescence nucleic acid dye recently engineered by Biotium company (Fremont, CA). This method, hereinafter referred to as GelGreen method, provides a fast (∼30 min) and reliable strategy for AAV titration. To validate GelGreen method, we measured genome titer of an AAV reference material AAV8RSM and compared our titration results with those determined by Reference Material Working Group (ARMWG). We showed that GelGreen results and capsid enzyme-linked immunosorbent assay results are comparable with each other. We also showed that GelRed® dye, a red fluorescence dye from Biotium, can be used to directly “visualize” AAV genome titer on a conventional gel imager, presenting an especially direct approach to estimate viral quantity. Finally, we showed that GelGreen and GelRed dyes can also be used to quantify self-complementary AAV (scAAV) and crudely purified AAV samples. In summary, we described a technique to titer AAV by using new generation of safe DNA dyes. This technique is simple, safe, reliable, and cost efficient. It has potential to be broadly applied for quantifying and normalizing AAV viral vectors.
Get full access to this article
View all access options for this article.
References
1.
ZinnE, VandenbergheLH. Adeno-associated virus: fit to serve. Curr Opin Virol, 2014; 8:90–97.
2.
BetleyJN, SternsonSM. Adeno-associated viral vectors for mapping, monitoring, and manipulating neural circuits. Hum Gene Ther, 2011; 22:669–677.
3.
HermonatPL, MuzyczkaN. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci U S A, 1984; 81:6466–6470.
4.
KaplittMG, LeoneP, SamulskiRJ, et al.Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet, 1994; 8:148–154.
5.
WangD, TaiPWL, GaoG. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov, 2019; 18:358–378.
6.
DayTP, ByrneLC, SchafferDV, et al.Advances in AAV vector development for gene therapy in the retina. Adv Exp Med Biol, 2014; 801:687–693.
7.
FlotteT, CarterB, ConradC, et al.A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther, 1996; 7:1145–1159.
8.
BennicelliJ, WrightJF, KomaromyA, et al.Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther, 2008; 16:458–465.
9.
CideciyanAV, AlemanTS, BoyeSL, et al.Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A, 2008; 105:15112–15117.
10.
HauswirthWW, AlemanTS, KaushalS, et al.Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther, 2008; 19:979–990.
11.
SamulskiRJ, ChangLS, ShenkT. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol, 1989; 63:3822–3828.
12.
SondhiD, PetersonDA, GiannarisEL, et al.AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. Gene Ther, 2005; 12:1618–1632.
13.
GrimmD, KernA, PawlitaM, et al.Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther, 1999; 6:1322–1330.
14.
ZeltnerN, KohlbrennerE, ClementN, et al.Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors. Gene Ther, 2010; 17:872–879.
15.
AurnhammerC, HaaseM, MuetherN, et al.Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Hum Gene Ther Methods, 2012; 23:18–28.
16.
GriegerJC, ChoiVW, SamulskiRJ. Production and characterization of adeno-associated viral vectors. Nat Protoc, 2006; 1:1412–1428.
17.
VeldwijkMR, TopalyJ, LaufsS, et al.Development and optimization of a real-time quantitative PCR-based method for the titration of AAV-2 vector stocks. Mol Ther, 2002; 6:272–278.
18.
SommerJM, SmithPH, ParthasarathyS, et al.Quantification of adeno-associated virus particles and empty capsids by optical density measurement. Molecular Ther, 2003; 7:122–128.
19.
PiedraJ, OntiverosM, MiravetS, et al.Development of a rapid, robust, and universal picogreen-based method to titer adeno-associated vectors. Hum Gene Ther Methods, 2015; 26:35–42.
20.
KohlbrennerE, HenckaertsE, RaptiK, et al.Quantification of AAV particle titers by infrared fluorescence scanning of coomassie-stained sodium dodecyl sulfate-polyacrylamide gels. Hum Gene Ther Methods, 2012; 23:198–203.
21.
AyusoE, MingozziF, MontaneJ, et al.High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Ther, 2010; 17:503–510.
22.
ZenZ, EspinozaY, BleuT, et al.Infectious titer assay for adeno-associated virus vectors with sensitivity sufficient to detect single infectious events. Hum Gene Ther, 2004; 15:709–715.
MohiuddinI, LoilerS, ZolotukhinI, et al.Herpesvirus-based infectious titering of recombinant adeno-associated viral vectors. Mol Ther, 2005; 11:320–326.
25.
WerlingNJ, SatkunanathanS, ThorpeR, et al.Systematic comparison and validation of quantitative real-time PCR methods for the quantitation of adeno-associated viral products. Hum Gene Ther Methods, 2015; 26:82–92.
26.
D'CostaS, BlouinV, BroucqueF, et al.Practical utilization of recombinant AAV vector reference standards: focus on vector genomes titration by free ITR qPCR. Mol Ther Methods Clin Dev, 2016; 5:16019.
27.
AyusoE, BlouinV, LockM, et al.Manufacturing and characterization of a recombinant adeno-associated virus type 8 reference standard material. Hum Gene Ther, 2014; 25:977–987.
28.
LockM, AlviraMR, ChenSJ, et al.Absolute determination of single-stranded and self-complementary adeno-associated viral vector genome titers by droplet digital PCR. Hum Gene Ther Methods, 2014; 25:115–125.
29.
DobnikD, KogovsekP, JakominT, et al.Accurate quantification and characterization of adeno-associated viral vectors. Front Microbiol, 2019; 10:1570.
30.
JonesLJ, GrayM, YueST, et al.Sensitive determination of cell number using the CyQUANT cell proliferation assay. J Immunol Methods, 2001; 254:85–98.
31.
DraganAI, Casas-FinetJR, BishopES, et al.Characterization of PicoGreen interaction with dsDNA and the origin of its fluorescence enhancement upon binding. Biophys J, 2010; 99:3010–3019.
32.
AhnSJ, CostaJ, EmanuelJR. PicoGreen quantitation of DNA: effective evaluation of samples pre- or post-PCR. Nucleic Acids Res, 1996; 24:2623–2625.
33.
SamulskiRJ, MuzyczkaN. AAV-mediated gene therapy for research and therapeutic purposes. Annu Rev Virol, 2014; 1:427–451.
34.
XiaoX, LiJ, SamulskiRJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol, 1998; 72:2224–2232.
35.
ZhuY, XuJ, HauswirthWW, et al.Genetically targeted binary labeling of retinal neurons. J Neurosci, 2014; 34:7845–7861.
36.
JaraJH, StanfordMJ, ZhuY, et al.Healthy and diseased corticospinal motor neurons are selectively transduced upon direct AAV2-2 injection into the motor cortex. Gene Ther, 2016; 23:272–282.
37.
ZolotukhinS, ByrneBJ, MasonE, et al.Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther, 1999; 6:973–985.
38.
KohlbrennerE, WeberT. Production and characterization of vectors based on the cardiotropic AAV serotype 9. Methods Mol Biol, 2017; 1521:91–107.
39.
McCartyDM, MonahanPE, SamulskiRJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther, 2001; 8:1248–1254.
40.
WangZ, MaHI, LiJ, et al.Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther, 2003; 10:2105–2111.
41.
XuJ, ZhuY. A rapid in vitro method to flip back the double-floxed inverted open reading frame in a plasmid. BMC Biotechnol, 2018; 18:52.
42.
BurgerC, GorbatyukOS, VelardoMJ, et al.Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther, 2004; 10:302–317.
LockM, McGorrayS, AuricchioA, et al.Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. Hum Gene Ther, 2010; 21:1273–1285.
45.
FrançoisA, BouzelhaM, LecomteE, et al.Accurate titration of infectious AAV particles requires measurement of biologically active vector genomes and suitable controls. Mol Ther Methods Clin Dev, 2018; 10:223–236.
46.
Penaud-BudlooM, BroucqueF, HarrouetK, et al.Stability of the adeno-associated virus 8 reference standard material. Gene Ther, 2019; 26:211–215.
47.
BennettA, PatelS, MietzschM, et al.Thermal stability as a determinant of AAV serotype identity. Mol Ther Methods Clin Dev, 2017; 6:171–182.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
